Solutions
About Us
Insights
Careers

Parent-of-origin effects in the life-course evolution of cardiometabolic traits. Wagh R, Hatem G, Andersson J, Kunte P, Bandyopadhyay S, Yajnik CS, Prasad RB. Diabetologia. 2025

Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR. Laidlaw TM, Buchheit KM, Cahill KN, Bernstein JA, Martin NL, Roseti SL, Lindsley AW, Ambrose CS. J Allergy Clin Immunol Pract. 2025

Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study. Bolleddula J, Scheible H, Huber F, Seithel-Keuth A, Schieferstein H, Vagge DS, Mammasse N, Jaks E, Ferrer J, Moulin C, Dong J, Venkatakrishnan K, Papai Z. Clin Pharmacol Drug Dev. 2025

Combined Immediate-Release and Extended-Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation. Ahuja N, Kääriäinen S, Lovró Z, Lundblad M, Drott K, Lilienberg E, Engström MT, Saukkonen K, Scheinin M. Clin Pharmacol Drug Dev. 2025

The modified combo i3 + 3 design for novel-novel combination dose-finding trials in oncology. Liu J, Yuan S, Deng Q, Ji Y. Contemp Clin Trials. 2025

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies. Pavord ID, Brightling CE, Korn S, Martin NL, Ponnarambil SS, Molfino NA, Parnes JR, Ambrose CS. Pulm Ther. 2025

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK. J Clin Oncol. 2025

Parent-of-origin effects in the life-course evolution of cardiometabolic traits. Wagh R, Hatem G, Andersson J, Kunte P, Bandyopadhyay S, Yajnik CS, Prasad RB. Diabetologia. 2025

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Therapeutic Advances in Neurological Disorders. 2025

Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces temperature-evoked pain in patients with peripheral neuropathic pain with sensory hypersensitivity, a randomized, double-blind, placebo-controlled, crossover study. Miclescu A, Karlsten R, Lönnstedt I, Halldin MM, Segerdahl M. Scandinavian Journal of Pain. 2025